Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ('BACKBEAT Trial”) by the end of Q3 2026 Orchestra BioMed and Medtronic plc. (NYSE: MDT, 'Medtronic”), the Company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results